Progression to castration-resistance and metastatic disease following androgen deprivation therapy for biochemical recurrence after prostate cancer surgery.
In this large national cohort of men with biochemical recurrence after surgery, most did not develop metastatic disease during nearly 10 years of follow up and one in four patients were treated with androgen deprivation therapy.